Critical Review: Hyperfine (NASDAQ:HYPR) & CardioGenics (OTCMKTS:CGNH)

Hyperfine (NASDAQ:HYPR) and CardioGenics (OTCMKTS:CGNH) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.

Earnings and Valuation

This table compares Hyperfine and CardioGenics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40 million	12.02	-$35.57 million	($0.41)	-3.37
CardioGenics	N/A	N/A	N/A	N/A	N/A

CardioGenics has lower revenue, but higher earnings than Hyperfine.

Profitability

This table compares Hyperfine and CardioGenics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperfine	-226.88%	-98.83%	-67.09%
CardioGenics	N/A	N/A	N/A

Insider & Institutional Ownership

15.0% of Hyperfine shares are held by institutional investors. 26.3% of Hyperfine shares are held by company insiders. Comparatively, 41.4% of CardioGenics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for Hyperfine and CardioGenics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1	2	3	0	2.33
CardioGenics	0	0	0	0	0.00

Hyperfine currently has a consensus target price of $1.78, suggesting a potential upside of 29.23%. Given Hyperfine’s stronger consensus rating and higher possible upside, research analysts clearly believe Hyperfine is more favorable than CardioGenics.

Summary

Hyperfine beats CardioGenics on 5 of the 9 factors compared between the two stocks.

About Hyperfine

Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.

About CardioGenics

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.